
Jeffrey S Barrett

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8347710/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer. Journal of Clinical Oncology, 2004, 22, 2336-2347.	1.6	506
2	Randomized Phase 2 Trial To Evaluate the Clinical Efficacy of Two High-Dosage Tigecycline Regimens versus Imipenem-Cilastatin for Treatment of Hospital-Acquired Pneumonia. Antimicrobial Agents and Chemotherapy, 2013, 57, 1756-1762.	3.2	208
3	Lower Malignancy Rates in Renal Allograft Recipients Converted to Sirolimus-Based, Calcineurin Inhibitor-Free Immunotherapy: 24-Month Results From the CONVERT Trial. Transplantation, 2011, 92, 303-310.	1.0	198
4	Pharmacokinetics of Gemtuzumab Ozogamicin, an Antibody-Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First Relapse. Journal of Clinical Pharmacology, 2001, 41, 1206-1214.	2.0	124
5	The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. PLoS ONE, 2017, 12, e0175207.	2.5	92
6	Pharmacological and Patient-Specific Response Determinants in Patients with Hospital-Acquired Pneumonia Treated with Tigecycline. Antimicrobial Agents and Chemotherapy, 2012, 56, 1065-1072.	3.2	89
7	Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia. Haemophilia, 2005, 11, 571-582.	2.1	60
8	Pharmacokinetics of Gemtuzumab Ozogamicin as a Single-Agent Treatment of Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia. Journal of Clinical Pharmacology, 2004, 44, 873-880.	2.0	54
9	Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 535-548.	2.3	50
10	Pharmacokinetics-Pharmacodynamics of Tigecycline in Patients with Community-Acquired Pneumonia. Antimicrobial Agents and Chemotherapy, 2012, 56, 130-136.	3.2	44
11	Excretion of Moxidectin into Breast Milk and Pharmacokinetics in Healthy Lactating Women. Antimicrobial Agents and Chemotherapy, 2011, 55, 5200-5204.	3.2	41
12	Onceâ€weekly prophylactic treatment vs. onâ€demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B. Haemophilia, 2016, 22, 381-388.	2.1	41
13	Absence of a Pharmacokinetic Interaction between Etanercept and Warfarin. Journal of Clinical Pharmacology, 2004, 44, 543-550.	2.0	38
14	Tigecycline Population Pharmacokinetics in Patients with Community- or Hospital-Acquired Pneumonia. Antimicrobial Agents and Chemotherapy, 2010, 54, 5180-5186.	3.2	35
15	Absence of a Clinically Relevant Interaction Between Etanercept and Digoxin. Journal of Clinical Pharmacology, 2004, 44, 1244-1251.	2.0	34
16	Relative Bioavailability of Liquid and Tablet Formulations of the Antiparasitic Moxidectin. Clinical Pharmacology in Drug Development, 2012, 1, 32-37.	1.6	34
17	Evaluation of Tigecycline Penetration into Colon Wall Tissue and Epithelial Lining Fluid Using a Population Pharmacokinetic Model and Monte Carlo Simulation. Antimicrobial Agents and Chemotherapy, 2007, 51, 4085-4089.	3.2	33
18	Tigecycline Pharmacokinetics in Subjects With Various Degrees of Renal Function. Journal of Clinical Pharmacology, 2012, 52, 1379-1387.	2.0	32

JEFFREY S BARRETT

#	Article	IF	CITATIONS
19	Population Pharmacokinetics of Intravenous Amiodarone and Comparison with Two tage Pharmacokinetic Analysis. Journal of Clinical Pharmacology, 1997, 37, 610-617.	2.0	22
20	Pharmacokinetic and Pharmacodynamic Action of Etodolac in Patients after Oral Surgery. Journal of Clinical Pharmacology, 1999, 39, 729-737.	2.0	22
21	Elucidation of Factor VIII Activity Pharmacokinetics: A Pooled Population Analysis in Patients With Hemophilia A Treated With Moroctocog Alfa. Clinical Pharmacology and Therapeutics, 2017, 102, 977-988.	4.7	20
22	Effect of moxidectin on CYP3A4 activity as evaluated by oral midazolam pharmacokinetics in healthy subjects. Clinical Pharmacology in Drug Development, 2014, 3, 151-157.	1.6	19
23	Integrated Population Pharmacokinetics of Etanercept in Healthy Subjects and in Patients With Rheumatoid Arthritis Ankylosing Spondylitis. Journal of Clinical Pharmacology, 2011, 51, 864-875.	2.0	17
24	The Path to Perfect Pediatric Posology — Drug Development in Pediatrics. Journal of Clinical Pharmacology, 2018, 58, S48-S57.	2.0	15
25	Reassessment of tigecycline bone concentrations in volunteers undergoing elective orthopedic procedures. Journal of Clinical Pharmacology, 2014, 54, 70-74.	2.0	13
26	Population pharmacokinetic modelling of factor <scp>IX</scp> activity after administration of recombinant factor <scp>IX</scp> in patients with haemophilia B. Haemophilia, 2016, 22, e359-66.	2.1	10
27	Confirmation of longer FIX activity half-life with prolonged sample collection after single doses of nonacog alfa in patients with haemophilia B. Thrombosis and Haemostasis, 2017, 117, 1052-1057.	3.4	10
28	The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers. European Journal of Clinical Pharmacology, 2013, 69, 835-842.	1.9	9
29	Tigecycline pharmacokinetics, tolerability, safety, and effect on intestinal microflora in healthy Japanese male subjects. Journal of Clinical Pharmacology, 2014, 54, 513-519.	2.0	9
30	Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings. Thrombosis and Haemostasis, 2015, 114, 676-684.	3.4	9
31	Evaluating Possible Pharmacokinetic Interactions between Tobramycin, Piperacillin, and a Combination of Piperacillin and Tazobactam in Patients with Various Degrees of Renal Impairment. Journal of Clinical Pharmacology, 2001, 41, 979-986.	2.0	8
32	Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B. Clinical Therapeutics, 2016, 38, 936-944.	2.5	7
33	Realâ€World Data: An Unrealized Opportunity in Global Health?. Clinical Pharmacology and Therapeutics, 2019, 106, 57-59.	4.7	7
34	Comparative Bioavailability Study of Single-Dose Film-Coated and Sugar-Coated Ethionamide Tablets in Healthy Volunteers. Clinical Therapeutics, 2014, 36, 982-987.	2.5	6
35	Steadyâ€state pharmacokinetics of sirolimus in stable adult Chinese renal transplant patients. Clinical Pharmacology in Drug Development, 2014, 3, 235-241.	1.6	5
36	Assessment of relative bioavailability of two presentations of moroctocog alfa (AF CC) in subjects with moderately severe or severe hemophilia A. Clinical Pharmacology in Drug Development, 2015, 4, 237-241.	1.6	5

JEFFREY S BARRETT

#	Article	IF	CITATIONS
37	Clinical experience with moroctocog alfa (<scp>AF</scp> â€ <scp>CC</scp>) in younger paediatric patients with severe haemophilia A: Two openâ€label studies. Haemophilia, 2018, 24, 604-610.	2.1	5
38	Repeat-dose sirolimus pharmacokinetics and pharmacodynamics in patients with hepatic allografts. European Journal of Clinical Pharmacology, 2012, 68, 589-597.	1.9	4
39	An Open-label, Single-dose, Pharmacokinetic Study of Factor VIII Activity After Administration of Moroctocog Alfa (AF-CC) in Male Chinese Patients With Hemophilia A. Clinical Therapeutics, 2017, 39, 1313-1319.	2.5	4
40	Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF C) in Subjects With Severe Hemophilia A. Clinical and Translational Science, 2018, 11, 283-288.	3.1	4
41	Assessment of the Effects of Age and Renal Function on Pharmacokinetics of Bazedoxifene in Postmenopausal Women. Clinical Pharmacology in Drug Development, 2018, 7, 920-926.	1.6	4
42	A Pilot Doseâ€Finding Study of Etanercept in Rheumatoid Arthritis. Clinical and Translational Science, 2018, 11, 38-45.	3.1	3
43	Don't Do Different Things…Do Things Differently! Drug Development in Rare Diseases. Clinical Pharmacology and Therapeutics, 2016, 100, 333-335.	4.7	2
44	Perspective on Dataâ€ 5 haring Requirements for the Necessary Evolution of Drug Development. Journal of Clinical Pharmacology, 2020, 60, 688-690.	2.0	2
45	Comparative Sirolimus Pharmacokinetics After Single-Dose Administration of Two Prototype 0.5-mg Tablets in Healthy Volunteers. Clinical Pharmacology in Drug Development, 2012, 1, 52-6.	1.6	1
46	Peptides, mAbs, bispecifics, oh my! clinical pharmacology challenges in the development of biologics. Journal of Clinical Pharmacology, 2015, 55, S1-3.	2.0	1
47	Industry Perspective of Drug Development for Pregnant/Breastfeeding Women. Clinical Pharmacology and Therapeutics, 2016, 100, 19-21.	4.7	1
48	A single-arm, open-label study to assess the immunogenicity, safety, and efficacy of etanercept manufactured using the serum-free, high-capacity manufacturing process administered to patients with rheumatoid arthritis. European Journal of Rheumatology, 2019, 6, 23-28.	0.6	1
49	Impact of treatment regimen with moroctocog alfa (AFâ€CC) on bleeding rates in paediatric patients with severe haemophilia A. Haemophilia, 2020, 26, e232-e235.	2.1	Ο